A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis
Status:
Not yet recruiting
Trial end date:
2023-08-30
Target enrollment:
Participant gender:
Summary
This is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single and Multiple
AscendingDose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and
Pharmacodynamics of ICP-488 in Healthy Subjects and Patients With Psoriasis